BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase

References

• GoldhirschAIngleJNGelberRDCoatesASThürlimannBSennHJPanel membersThreshold for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancerAnn Oncol20092081319132919535820
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• LudwigCStoelbenEHasseJDisease-free survival after resection of lung metastases in patients with breast cancerEur J Surg Oncol200329653253512875861
   PubMed Web of Science ®Google Scholar
• HoeALRoyleGTTaylorIBreast liver metastases – incidence, diagnosis and outcomeJ R Soc Med199184127147161774744
   PubMed Web of Science ®Google Scholar
• BoogerdWHartAATjahjaISTreatment and outcome of brain metastasis as first site of distant metastasis from breast cancerJ Neurooncol19973521611679266454
   PubMed Web of Science ®Google Scholar
• JørgensenCLNielsenTOBjerreKDPAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patientsActa Oncol201453677678724359601
   PubMed Web of Science ®Google Scholar
• SledgeGWJrLoehrerPJSrRothBJEinhornLHCisplatin as first-line therapy for metastatic breast cancerJ Clin Oncol1988612181118143199166
   PubMed Web of Science ®Google Scholar
• VogelCLNabholtzJMMonotherapy of metastatic breast cancer: a review of newer agentsOncologist199941173310337368
   PubMedGoogle Scholar
• ErshlerWBCapecitabine monotherapy: safe and effective treatment for metastatic breast cancerOncologist200611432533516614228
   PubMed Web of Science ®Google Scholar
• LaoJMadaniJPuértolasTLiposomal doxorubicin in the treatment of breast cancer patients: a reviewJ Drug Deliv2013201345640923634302
   PubMedGoogle Scholar
• TuxenMKColdSTangeUBBalslevENielsenDLPhase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancerActa Oncol201453101440144524991893
   PubMed Web of Science ®Google Scholar
• ShulmanLNBerryDACirrincioneCTComparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance)J Clin Oncol201432222311231724934787
   PubMed Web of Science ®Google Scholar
• DewiSLarsenSSrimuninnimitVLuYSManuabaTLindkaer-JensenSBenzene-poly-carboxyli acid complex with cis-diammineplatinum (II) dichloride in the treatment of stage IV breast cancer patientsThe Open Breast Cancer Journal20135715
   Google Scholar
• CarlsenKHKramerJFagertunHELarsenSLoratadine and terfenadine in perennial allergic rhinitis. Treatment of nonresponders to the one drug with the other drugAllergy19934864314368238798
   PubMed Web of Science ®Google Scholar
• PocockSJClinical Trials: A Practical ApproachNew York, NYJohn Wiley & Sons Ltd1989
   Google Scholar
• AltmanDGPractical Statistics for Medical ResearchLondon, UKChapman and Hall1990
   Google Scholar
• AgrestiACategorical Data Analysis2nd edHoboken, NJJohn Wiley & Sons2002
   Google Scholar
• Conclusions and recommendations Panel on Handling Missing Data in Clinical Trials and Committee on National Statistics The Prevention and Treatment of Missing Data in Clinical Trials2010National Academy Press2011110112
   Google Scholar
• ShaoJZhongBLast observation carry-forward and last observation analysisStat Med200322152429244112872300
   PubMed Web of Science ®Google Scholar
• TabachnickBGFidellLSUsing Multivariate Statistics5th edBoston, MAPearson Education, Inc2007
   Google Scholar
• PoulsenLPatients with breast cancer are treated at homeSygeplejersken201457885
   Google Scholar
• Gonzalez-AnguloAMMorales-VasquezFHortobagyiGNOverview of resistance to systemic therapy in patients with breast cancerAdv Exp Med Biol200760812217993229
   PubMed Web of Science ®Google Scholar
• PerminovaIVInteraction of 3H-Labeled Benzene-Polycarboxylic Acids (BP-Cx-1) with Tumours and Normal Cell CulturesReport Moscow State University2012
   Google Scholar
• FaresFAzzamNFaresBLarsenSLindkaer-JensenSBenzene-poly-carboxylic acid complex, a novel anti-cancer agent induces apoptosis in human breast cancer cellsPLoS One201492e8515624523856
   PubMed Web of Science ®Google Scholar
• KirkinADzhandzhugazyanKNFangJJLindkaer-JensenSBenzene-poly-carboxylic acids complex with cis-diammineplatinum [II] dichloride [BP-C1], an innovative anti-cancer agent, activates multiple immunological mechanisms of an antitumor responseInternational Biologics: Target and Therapy In press2014
   Google Scholar
• GuarneriVContePFThe curability of breast cancer and the treatment of advanced diseaseEur J Nucl Med Mol Imaging200431Suppl 1S149S16115107948
   PubMed Web of Science ®Google Scholar
• MillerABWallCBainesCJSunPToTNarodSATwenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trialBMJ2014348g36624519768
   PubMed Web of Science ®Google Scholar
• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• ChengYCUenoNTImprovement of survival and prospect of cure in patients with metastatic breast cancerBreast Cancer201219319119921567170
   PubMed Web of Science ®Google Scholar
• CameronDAGabraHLeonardRCContinuous 5-fluorouracil in the treatment of breast cancerBr J Cancer19947011201248018521
   PubMed Web of Science ®Google Scholar
• CareyLARugoHSMarcomPKTBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancerJ Clin Oncol201230212615262322665533
   PubMed Web of Science ®Google Scholar